

Evaluation of Predictors for the Development and Progression of Diabetic Retinopathy among Diabetes Mellitus Type 2 Patients

Syafawati Ab Saad¹, Maz Jamilah Masnan^{1,2}, Karniza Khalid³ and Safwati Ibrahim¹

¹Faculty of Applied & Human Sciences, Institute of Engineering Mathematics, Universiti Malaysia Perlis, Kampus Alam UniMAP, Pauh Putra, 02600 Arau, Perlis, Malaysia

²Centre of Excellence for Social Innovation and Sustainability, Universiti Malaysia Perlis, Kampus Alam UniMAP, Pauh Putra, 02600 Arau, Perlis, Malaysia

³Ministry of Health Malaysia, Clinical Research Centre, Hospital Tuanku Fauziah, Jalan Tun Abd Razak, 01000 Kangar, Perlis, Malaysia

* Corresponding author: syafawatisaad@unimap.edu.my

Received: 25 October 2021; Accepted: 12 November 2021; Available online (In press): 23 June 2022

ABSTRACT

Diabetic retinopathy is one of the microvascular complications caused by prolonged uncontrolled diabetes. It is believed that diabetic retinopathy correlates with certain predictors and risk factors that might worsen the disease, eventually causing visual loss and blindness among diabetes patients. There are some predictors and risk factors that attribute to the development and progression of diabetic retinopathy, such as the duration of diabetes and HbA1c trends. This study aims to evaluate the predictors and risk factors associated with the development and/or progression of diabetic retinopathy. Retrospective data were collected from a single healthcare facility in the northwest of Peninsular Malaysia. Patients included in this study were those with type 2 diabetes mellitus diagnosed with diabetic retinopathy. The total number of patients involved in this study were 197, where 161 of them were newly diagnosed or with progressive diabetic retinopathy. The characteristics of diabetes patients with complication of diabetic retinopathy were described through descriptive statistics. Characteristics include demographics data such as age, gender, race and clinical data such as HbA1c readings HbA1c, estimated glomerular filtration rate (eGFR), urea and haemoglobin concentration (Hb). The results show that 7 predictors and risk factors are significant to the development and progression of diabetic retinopathy among diabetes patients. By using multinomial logistic regression, this study offers better understanding of the significant predictors and risk factors related to diabetic retinopathy.

Keywords: diabetic retinopathy, predictors, multinomial logistic regression

1 INTRODUCTION

Diabetic retinopathy is a microvascular complication caused by prolonged uncontrolled diabetes mellitus which may cause significant disability including blindness. The prevalence of diabetic retinopathy worldwide ranges from 6.8% to 44.4% in patients with diabetes mellitus. Globally, the number of people with diabetic retinopathy were estimated to grow from 126.6 million in 2010 to 191.0 million by 2030 if remedial action is not taken [1], [2]. However, in Malaysia the prevalence of diabetic retinopathy has been reported to increase from 44.1% to 48.6% [3]. The prevalence of diabetic retinopathy in Malaysia is comprised of 12.3% of type 1 and another 22.3% of type 2 diabetes mellitus. Diabetic retinopathy refers to all the vascular changes in the retina occurring from the disease detected from ophthalmologic evaluation, risking visual impairment

and blindness among patients with diabetes [4]. According to the International Clinical Diabetic Retinopathy, diabetic retinopathy is categorized by six stages; (i) no retinopathy, (ii) mild non-proliferative diabetic retinopathy (NPDR), (iii) moderate NPDR, (iv) severe NPDR, (v) proliferative diabetic retinopathy (PDR) and (vi) advanced diabetic eye disease (ADED)[5].

From past studies, predictors and risk factors that are commonly associated to the progression of diabetic retinopathy includes the duration of diabetes, age, gender, HbA1c and hypertension [3],[6],[7],[8],[9]. In addition, there are clinical predictors which can be significant to the development of diabetic retinopathy. Common clinical predictors that may affect the progression of diabetic retinopathy are glycosylated haemoglobin trends (HbA1c), systolic and diastolic blood pressure, serum creatinine and urea [10]. Synonymously, [11], [12], [13] agreed that blood glucose control as measured by HbA1c, insulin treatment, glucose levels and serum creatinine could also impact the progression of diabetic retinopathy. However, the testing on the significance of these predictors varied from one study to another.

Diabetes patients with diabetic retinopathy can be divided into three groups. Group 1 include diabetes patients who were diagnosed with diabetes without obvious clinical findings of diabetic retinopathy (show development). Unfortunately, some of them may have developed occult signs of early diabetic retinopathy. While Group 2 consists of diabetes patients who were diagnosed with diabetic retinopathy and remain in the same stage for a certain period of time until the current follow-up, and Group 3 involves diabetes patients who were diagnosed with diabetic retinopathy at certain stage for a period of time but progressively worsen over time during the current follow-up (show progression). Thus, the purpose of this study is to evaluate the predictors and risk factors associated to the development or progression of diabetic retinopathy among Group 1 and Group 3. However, for the descriptive statistics, analysis will involve all the three groups.

2 STUDY DESIGN

This is a retrospective study involving patients with diabetes mellitus type 2 (T2DM) from a single healthcare centre located in the northwest of Peninsular Malaysia. A total of 197 diabetes patients were included in this study. The characteristics of patients selected in this study were; diabetes patients who were diagnosed with diabetic retinopathy, on follow-up treatment in the respective healthcare centre from their first clinic visit, up to the year 2020. Predictors and risk factors evaluated in this study are age, gender, ethnicity, duration of T2DM, duration of diabetic retinopathy, diabetic nephropathy, hypertension, dyslipidaemia, HbA1c, estimated glomerular filtration rate (eGFR), urea and haemoglobin concentration (Hb). The details and clinical data for every patient were obtained from their medical card, which was recorded by trained and credentialed personnel, with prior review by experienced ophthalmologists at the Ophthalmologist Clinic.

3 STATISTICAL ANALYSIS

Evaluation for significant predictors and risk factors for this study was implemented by modelling the multinomial logistic regression model using the predictors and risk factors involved in the study. Multinomial logistic regression is an extension of binary logistic regression that allows more than two categories of dependent variable. Commonly, multinomial logistic regression model is applied for classification in medical, education, transportation, physiological, mathematical finance and engineering area. Multinomial logistic is also known as the polytomous

or multiclass logistic regression method. In order to make sure valid results are obtained from the model, all the six assumptions of the model including, (i) the dependent variable i.e. stages of diabetic retinopathy should be measured at the nominal level, (ii) the model has one or more independent variables i.e. predictors and risk factors that are continuous, ordinal or nominal, (iii) the model has independence of observations and the stages of diabetic retinopathy should have mutually exclusive and exhaustive categories, (iv) there should be no multicollinearity among the predictors and risk factors, (v) there needs to be a linear relationship between any continuous predictors and risk factors, and the logit transformation of the stages of diabetic retinopathy, and (vi) there should be no outliers for the scale or continuous variables. Multinomial logistic regression model is presented as:

$$logit(Y_{DR}) = ln\left[\frac{P(Y_{DR} = j | X)}{P(Y_{DR} = J | X)}\right] = \beta_{j0} + \beta_{j1}X_1 + \beta_{j2}X_2 + ... + \beta_{jk}X_k$$
(1)

where j=1,2,...,J-1 is a logit equation and *J* represents the categories of the reference outcome. Y_{DR} includes the categorical predictors which represent the stages of diabetic retinopathy (no diabetic retinopathy (stage 0), mild NPDR (stage 1), moderate NPDR (stage 2), severe NPDR (stage 3), PDR (stage 4) and ADED (stage 5); Y=0,1,2,3,4,5. *X* refers to the predictors and risk factors associated with diabetic retinopathy, while *k* denotes the number of predictors and risk factors for diabetic retinopathy, where $X_1, X_2, ..., X_k$ can either be continuous or categorical predictors (replaced by dummy variables) and risk factors. Predictors and risk factors in this study include age, gender, ethnicity, duration of T2DM, duration of diabetic retinopathy, diabetic nephropathy, hypertension, dyslipidaemia, HbA1c, eGFR, Urea and Hb. β_{ik} is the logit coefficient

providing information on how great a change in the logit is made by a one-unit increase of the value of *k*-th predictors. This study used R Studio Packages to perform the respective statistical analyses.

4 RESULT AND DISCUSSION

For this study, progression of diabetic retinopathy refers to diabetes patients in Group 1 and Group 3, while diabetes patients in Group 2 shows no progression. Figure 1 shows the composition of diabetes patients according to the age group. Among diabetes patients in Group 1 and 3, the blue bars indicate that most number of patients with the age group from 50 to 89 years are among those who have higher potential of showing diabetic retinopathy progression. Compared to the red bars that reflect diabetes patients in Group 2, the number of patients with age 60 to 69 shows no progression in diabetic retinopathy. While Figure 2 illustrates that the number of male and female diabetes patients are similar regardless whether patients are in Group 1, 2 or 3.



Figure 1. Comparison between diabetes patients with no progression and with progression status according to patients' age group.







Figure 3. Comparison between no progression and with progression status according to ethnicity

Figure 3 demonstrates the ethnicity of diabetes patients involved in the study. Malay diabetes patients show the highest number of patients experiencing progressive diabetic retinopathy. Similar observation was also noted for diabetes patients with no progression. Based on the data, mostly malay patients are among the majority who come for follow up at the Ophthalmologist Clinic.

Figure 4(a) refers to the stages for diabetes patients when first diagnosed with diabetic retinopathy, while Figure 4(b) refers to the same diabetes patients when diagnosed with diabetic retinopathy during the current follow up. Based on Figure 4(a), diabetes patients with stage 0 are those who have higher potential to develop diabetic retinopathy. This means that if a patient in Group 1 have not yet diagnosed with diabetic retinopathy, he/she may develop to other stage of diabetic retinopathy after certain period of time. For example, a patient could present with no diabetic retinopathy initially, however may progressed directly to stage 2 (mild NPDR) or stage 3 (moderate NPDR). Figure 4(b) shows the increasing number of diabetes patients who have shown some stage progression. For example, about 118 diabetes patients who were first diagnosed with stage 0 have shown progression to stage 1, 10 patients have developed to stage 2, 11 patients developed to stage 3, and 15 patients developed to stage 4. Also, from Figure 4(b) one patients has shown progression from stage 4 to 5. Compared with no progression case for stages at diagnosis during the current follow up, the number of patients with no progression is higher for stage 2 (mild NPDR) and onwards.



Figure 4: Comparison between the (a) developed stages at diagnosis of diabetic retinopathy and (b) stages diabetic retinopathy at current follow up.

4.1 Comparison of Demographic and Clinical Data between Patients with and without Development or Progression of Diabetic Retinopathy

As mentioned earlier, this study includes three groups of patients; Group 1 includes diabetes patients who were diagnosed with diabetes but not yet diagnosed with diabetic retinopathy (show development), Group 2 refers to diabetes patients who were diagnosed with diabetic retinopathy and remain in the same stage for a certain period of time until the current follow-up, and Group 3 involves diabetes patients who were diagnosed with diabetic retinopathy at certain stage for a period of time but worsen to other stage during the current follow-up (show progression). A total of 197 patients with diabetes, 81.7% were patients from Group 1 and 3, while 18.3% from Group 2. From Table 1, the mean age for both groups is similar (67 years). However, the duration of diabetes, HbA1c, eGFR, urea and HB readings baseline for patients in Group 1 and 3 is higher than the readings for Group 3.

In addition, Table 1 shows the descriptive statistics and the significant predictors and risk factors for diabetes patients in Group 1 and 3 based on the evaluation using multinomial logistic regression model. These significant predictors and risk factors were tested based on the small p-value (<0.001). From 11 predictors evaluated, 7 predictors were found significant. Age, gender, duration of T2DM, duration diabetic retinopathy, HbA1c, eGFR, and urea are significant predictors for the development and progression of diabetic retinopathy. Some of these findings were found to be similar with the previous studies. Many studies have shown that duration of diabetes and gender are significant [8], [14], [15], [16]. While for the clinical data (HbA1c, eGFR and urea) some of studies agreed that HbA1c greatly influenced the progression of diabetic retinopathy [8], [14], [17]. This study highlights that eGFR and urea as new significant predictors to the progression of diabetic retinopathy among Group 1 and 3. This new finding are less discussed in the previous studies may be due to its effect to diabetic retinopathy.

Table 1 Characteristics of diabetic patients according to development or progression of diabetic retinopathy or without development or progression of diabetic retinopathy. (Group 1 - diabetes patients who were diagnosed with diabetes without obvious clinical findings of diabetic retinopathy (show development), Group 2 - diabetes patients who were diagnosed with diabetic retinopathy and remain in the same stage for a certain period of time until the current follow-up and Group 3 - diabetes patients who were diagnosed with diabetic retinopathy at certain stage for a period of time but progressively worsen over time during the current follow-up (show progression)). Values are proportions and means (standard deviations).

Characteristics	All	Group 1 & 3	Group 2	P-value
	Patients	Patients with	Patients without	
	(n=197)	Development/Progre	Development/Progres	
		ssion of Diabetic	sion of Diabetic	
		Retinopathy	Retinopathy	
		(n=161)	(n=36)	
Age	67.33	67.68 (11.02)	67.78 (11.02)	< 0.001
	(10.99)			
Gender				< 0.001
Male	0.52	0.53	0.42	
Female	0.48	0.47	0.58	
Ethnicity				0.9636
Malay	0.89	0.88	1.00	
Chinese	0.05	0.07		
India	0.03	0.01		
Others	0.02	0.01		
Duration of	12.66	13.31 (5.00)	12.52 (5.05))	< 0.001
T2DM	(5.03)			
Duration	6.02	6.79 (3.99)	5.96 (3.38)	< 0.001
Diabetic	(3.45)			
Retinopathy				
Diabetic	1.00	0.82	0.18	0.4392
Nephropathy				
Hypertension	0.99	0.82	0.18	0.576
Dyslipidaemia	0.89	0.91	0.20	0.6231
HbA1c	8.64	9.41 (2.50)	8.54 (2.47)	< 0.001
	(2.47)			
eGFR	59.45	59.78 (25.37)	54.54 (23.47)	< 0.001
	(25.34)			
Urea	7.04	7.82 (3.93)	7.44 (3.94)	< 0.001
	(3.77)			
Hb	11.46	11.34 (2.00)	11.89 (1.97)	0.8069
	(2.01)			

5 CONCLUSION

This study found that age, gender, duration of T2DM, duration of diabetic retinopathy, HbA1c, eGFR and urea are significant to the progression of diabetic retinopathy. Overall, this results suggest that for high risk diabetic retinopathy patients, these predictors could potentially influence to the development of severe stage of diabetic retinopathy. Therefore, to avoid rapid progression of stages in diabetic retinopathy among diabetes patients, these significant predictors and risk factors need to be given attention to prevent serious microvascular complications.

ETHICAL CLEARANCE

This study was registered with the National Medical Research Register of the Ministry of Health, Malaysia (NMRR-19-3896-47105) and received ethical clearance from the Medical Research and Ethics Committee (MREC) of the Ministry of Health Malaysia (KKM/NIHSEC/P20-376).

ACKNOWLEDGMENT

The authors would like to thank the Director General of Health Malaysia for his permission to publish this paper. The authors also gratefully acknowledge to Doctor Muhamad Ruzaini Abd Hamid from Department of Ophthalmology, Hospital Tuanku Fauziah, Perlis and Doctor Noorhafini Abdul Sukur from Department of Internal Medicine, Hospital Tuanku Fauziah, Perlis for their support to this study.

REFERENCES

- [1] P. Romero-Aroca, M. Baget-Bernaldiz, J. Reyes-Torres, J. Fernandez-Ballart, N. Plana-Gil, I. Mendez-Marin, and A. Pareja-Rios, "Relationship between diabetic retinopathy, microalbuminuria and overt nephropathy, and twenty-year incidence follow-up of a sample of type 1 diabetic patients," *Journal of Diabetes and its Complications*, vol. 26, no. 6, pp. 506–512, 2012.
- [2] J. Zhang, Y. Wang, L. Li, R. Zhang, R. Guo, H. Li, Q. Han, G. Teng, and F. Liu, "Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy," *Renal Failure*, vol. 40, no. 1, pp. 243–251, 2018.
- [3] M. H. Mohd Ali, N. Draman, W. M. I. W. Mohamed, A. Yaakub, and Z. Embong, "Predictors of proliferative diabetic retinopathy among patients with type 2 diabetes mellitus in Malaysia as detected by fundus photography," *Journal of Taibah University Medical Sciences*, vol. 11, no. 4, pp. 353–358, 2016.
- [4] F. Altomare, A. Kherani, and J. Lovshin, "Retinopathy," *Canadian Journal of Diabetes*, vol. 42, pp. S210–S216, 2018.
- [5] P. P. Goh, "Status of Diabetic Retinopathy Among Diabetics Registered to the Diabetic Eye Registry, National Eye Database 2007," *Med J. Malaysia*, vol. 63, suppl. C, pp. 24–28, 2008.

- [6] Y. J. Kim, J.-G. Kim, J. Y. Lee, K. S. Lee, S. G. Joe, J.-Y. Park, M.-S. Kim, and Y. H. Yoon, "Development and progression of diabetic retinopathy and associated risk factors in Korean patients with type 2 diabetes: The experience of a tertiary center," *Journal of Korean Medical Science*, vol. 29, no. 12, p. 1699, 2014.
- [7] Y. Liu, J. Yang, L. Tao, H. Lv, X. Jiang, M. Zhang, and X. Li, "Risk factors of diabetic retinopathy and sight-threatening diabetic retinopathy: A cross-sectional study of 13 473 patients with type 2 diabetes mellitus in mainland China," *BMJ Open*, vol. 7, no. 9, 2017.
- [8] C. J. Rudnisky, B. K. Wong, H. Virani, and M. T. S. Tennant, "Risk factors for progression of diabetic retinopathy in Alberta First Nations communities," *Canadian Journal of Ophthalmology*, vol. 52, 2017.
- [9] J. Yau *et al.*, "Global prevalence and major risk factors of diabetic retinopathy," Diabetes care, vol. 35, no. 3, pp. 556–564, 2012. Doi: <u>https://doi.org/10.2337/dc11-1909</u>.
- [10] D. S. Fong, L. Aiello, T. W. Gardner, G. L. King, G. Blankenship, J. D. Cavallerano, and R. Klein, "Retinopathy in Diabetes," *Diabetes Care*, vol. 27, suppl. 1, pp. s84-s87, 2004.
- [11] W. J. Lee, L. Sobrin, M. J. Lee, M. H. Kang, M. Seong and H. Cho, "The relationship between diabetic retinopathy and diabetic nephropathy in a population-based study in Korea (KNHANES V-2, 3", *Investigative Ophthalmology & Visual Science*, vol. 55, no. 10, pp. 6547-6553, 2014.
- [12] P. Kotlarsky, A. Bolotin, K. Dorfman, B. Knyazer, T. Lifshitz and J. Levy, "Link between retinopathy and nephropathy caused by complications of diabetes mellitus type 2", *Int Ophthalmol*, vol. 35, no. 1, pp. 59-66, 2015.
- [13] H. Y. Tsao, P. Y. Chan and E. C. Y. Su, "Predicting diabetic retinopathy and identifying interpretable biomedical features using machine learning algorithms", *BMC Bioinformatics*, vol. 19, Supp. 9, pp. 198-205, 2018.
- [14] C. R. Cardoso, N. C. Leite, E. Dib, and G. F. Salles, "Predictors of development and progression of retinopathy in patients with type 2 diabetes: Importance of blood pressure parameters," *Scientific Reports*, vol. 7, no. 1, 2017.
- [15] S. Haider, S. N. Sadiq, E. Lufumpa, H. Sihre, M. Tallouzi, D. J. Moore, K. Nirantharakumar, and M. J. Price, "Predictors for diabetic retinopathy progression—findings from nominal group technique and evidence review," *BMJ Open Ophthalmology*, vol. 5, no. 1, 2020.
- [16] W. Kaewput, C. Thongprayoon, R. Rangsin, P. Ruangkanchanasetr, M. A. Mao, and W. Cheungpasitporn, "Associations of renal function with diabetic retinopathy and visual impairment in type 2 diabetes: A Multicenter nationwide cross-sectional study," World Journal of Nephrology, vol. 8, no. 2, pp. 33–43, 2019.
- [17] N. Euswas, N. Phonnopparat, K. Morasert, P. Thakhampaeng, A. Kaewsanit, M. Mungthin, R. Rangsin, and B. Sakboonyarat, "National trends in the prevalence of diabetic retinopathy among Thai patients with type 2 diabetes and its associated factors from 2014 to 2018," *PLOS ONE*, vol. 16, no. 1, 2021.

[18] W. Kaewput, C. Thongprayoon, R. Rangsin, P. Ruangkanchanasetr, M. A. Mao, and W. Cheungpasitporn, "Associations of renal function with diabetic retinopathy and visual impairment in type 2 diabetes: A Multicenter nationwide cross-sectional study," World Journal of Nephrology, vol. 8, no. 2, pp. 33–43, 2019.